These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39188553)

  • 1. Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation.
    Fonsi M; Fulbert J; Billat PA; Arbitrio M; Tagliaferri P; Tassone P; Di Martino MT
    Curr Res Pharmacol Drug Discov; 2024; 7():100197. PubMed ID: 39188553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.
    Di Martino MT; Arbitrio M; Fonsi M; Erratico CA; Scionti F; Caracciolo D; Tagliaferri P; Tassone P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861748
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
    Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate.
    Kang DW; Kim JH; Kim KM; Cho SJ; Choi GW; Cho HY
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
    J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
    Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
    Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
    Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
    Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling.
    Choi GW; Lee YB; Cho HY
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30959827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.
    Bhamidipati RK; Dravid PV; Mullangi R; Srinivas NR
    Xenobiotica; 2004 Jun; 34(6):571-9. PubMed ID: 15277016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data.
    Li C; Zhang C; Deng R; Leipold D; Li D; Latifi B; Gao Y; Zhang C; Li Z; Miles D; Chen SC; Samineni D; Wang B; Agarwal P; Lu D; Prabhu S; Girish S; Kamath AV
    Clin Transl Sci; 2019 Sep; 12(5):534-544. PubMed ID: 31115997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.
    Mahmood I; Balian JD
    Clin Pharmacokinet; 1999 Jan; 36(1):1-11. PubMed ID: 9989339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
    Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
    Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling.
    Sanwald-Ducray P; Dow J
    Xenobiotica; 1997 Feb; 27(2):189-201. PubMed ID: 9058532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allometric scaling for predicting human clearance of bisphenol A.
    Collet SH; Picard-Hagen N; Lacroix MZ; Puel S; Viguié C; Bousquet-Melou A; Toutain PL; Gayrard V
    Toxicol Appl Pharmacol; 2015 May; 284(3):323-9. PubMed ID: 25759244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study.
    Mahmood I
    J Pharm Pharmacol; 1999 Aug; 51(8):905-10. PubMed ID: 10504028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.